基线CTC低值的转移性去势抵抗性前列腺癌患者CTC增多可预测疾病进展
该研究对COU-AA-301与IMMC-38两项试验中基线CTC<5/7.5 mL的511例转移性去势抵抗性前列腺癌患者进行事后分析,评估治疗4、8或12周时CTC增多(CTC进展)与总生存的关系。结果显示CTC进展与显著更差的总生存相关,且独立于基线CTC和已知临床变量,并可改善预后模型的判别能力。
要点
- 基线CTC<5的患者中,治疗12周内CTC增多提示预后不良。
- CTC进展与总生存更差独立相关,HR 3.4(95%CI 2.5-4.5;P<0.001)。
- 将CTC进展纳入模型可提高ROC AUC(0.77 vs 0.66;P<0.001)。
核心结论
- 在基线CTC<5的转移性去势抵抗性前列腺癌患者中,治疗前12周内CTC增多与更差的总生存独立相关。
- CTC进展可改善包含已知预后变量的生存模型,但需前瞻性验证。
研究设计与样本
- 对COU-AA-301(阿比特龙或安慰剂+泼尼松)和IMMC-38(化疗)两项试验的事后分析。
- 共纳入511例基线CTC<5/7.5 mL的患者,其中COU-AA-301有421例,IMMC-38有90例。
主要发现
- 212例(41.7%)在治疗开始后4、8或12周出现CTC进展。
- CTC进展者总生存显著更差:27.1个月 vs 15.1个月;HR 3.4(95%CI 2.5-4.5;P<0.001)。
- CTC进展与总生存的关联独立于基线CTC和已知临床变量。
- 将CTC进展加入总生存模型显著提高ROC AUC(0.77 vs 0.66;P<0.001)。
- 包含CTC进展的模型ROC AUC(0.77 vs 0.69;P<0.001)和加权c-index(0.750 vs 0.705;delta c-index 0.045,95%CI 0.019-0.071)优于包含CTC转换(增至CTC≥5)的模型。
关键数值与推荐
- CTC进展定义为治疗开始后4、8或12周时CTC较基线增多。
- CTC进展与总生存更差相关:27.1个月 vs 15.1个月;HR 3.4(95%CI 2.5-4.5;P<0.001)。
- CTC进展模型ROC AUC为0.77,不含CTC进展模型为0.66(P<0.001)。
临床怎么用
- 对基线CTC<5的转移性去势抵抗性前列腺癌患者,治疗早期监测CTC增多有助于识别预后不良者。
- CTC进展可作为现有预后变量的补充,用于风险分层和疗效评估的参考。
局限性
- 本研究为对既往临床试验的事后分析。
- 研究结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a good prognosis subgroup but are non-evaluable for response assessment (decrease in CTCs). The aim of the study is to determine the value of any increase in CTCs (CTC progression) as an indicator of progression in prostate cancer patients with low pre-treatment CTCs (<5). PATIENTS AND METHODS: We carried out a post hoc analysis of patients with BLCTCs < 5 treated in the COU-AA-301 (abiraterone or placebo + prednisone) and IMMC-38 (chemotherapy) trials. The association of CTC progression (increase in CTCs at 4, 8 or 12 weeks) with overall survival (OS) was evaluated in multi-variable Cox regression models. Performance of survival models with and without CTC progression was evaluated by calculating ROC curve area under the curves (AUCs) and weighted c-indices. RESULTS: Overall, 511 patients with CTCs < 5 (421 in COU-AA-301 and 90 in IMMC-38) were selected; 212 (41.7%) had CTC progression at 4, 8 or 12 weeks after treatment initiation. CTC progression was associated with significantly worse OS [27.1 versus 15.1 m; hazard ratio (HR) 3.4 (95% confidence interval [CI] 2.5-4.5; P < 0.001)], independent of baseline CTCs and established clinical variables. Adding CTC progression to the OS model significantly improved ROC AUC (0.77 versus 0.66; P < 0.001). Models including CTC progression had superior ROC AUC (0.77 versus 0.69; P < 0.001) and weighted c-index [0.750 versus 0.705; delta c-index: 0.045 (95% CI 0.019-0.071)] values than those including CTC conversion (increase to CTCs ≥ 5). In COU-AA-301, the impact of CTC progression was independent of treatment arm. CONCLUSIONS: Increasing CTCs during the first 12 weeks of treatment are independently associated with worse OS from advanced prostate cancer in patients with baseline CTCs < 5 treated with abiraterone or chemotherapy and improve models with established prognostic variables. These findings must be prospectively validated.
引用
- Lorente D, Olmos D, Mateo J, et al. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Ann Oncol. 2018. PMID: 29741566. doi:10.1093/annonc/mdy172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。